Basel, Switzerland

Matthias Mehling

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Matthias Mehling: Innovator in Cancer Treatment

Introduction

Matthias Mehling is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of two patents, Mehling is dedicated to advancing medical science and improving patient outcomes.

Latest Patents

Mehling's latest patents focus on groundbreaking therapies for solid cancers. The first patent involves a combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) alongside immune checkpoint blockers. This invention aims to enhance treatment efficacy for patients suffering from various forms of cancer. The second patent addresses GDF-15 as a diagnostic marker to predict clinical outcomes for patients undergoing treatment with immune checkpoint blockers. This method provides valuable insights into treatment responses and survival probabilities for cancer patients.

Career Highlights

Matthias Mehling is affiliated with Julius-Maximilians-Universität Würzburg, where he conducts his research and develops his innovative therapies. His work has garnered attention in the medical community, contributing to advancements in cancer treatment methodologies.

Collaborations

Mehling collaborates with esteemed colleagues, including Jörg Wischhusen and Markus Haake. These partnerships enhance the research and development of effective cancer therapies, fostering a collaborative environment for innovation.

Conclusion

Matthias Mehling is a dedicated inventor whose work in cancer treatment is making a significant impact. His innovative patents and collaborations are paving the way for improved therapeutic strategies in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…